


## **Situation update on integrated sentinel surveillance of influenza and SARS-CoV-2 in SEAR Member States**

(As of September 2025, reported to FluMart of GISRS)

**Infectious Hazard Management (IHM)**  
WHO Health Emergency Programme  
[SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, SEAR



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, SEAR



Sub-types

Specimen test

ILI


SARI

SARS COV2


Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, SEAR



# Number of specimens positive for influenza by subtypes and the percentage positive, SEAR



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the percentage of ILI/SARI specimens positive for SARS- COV-2, SEAR




\*Includes Member states doing SARS-CoV2 testing part of Influenza sentinel surveillance.



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
 WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Bangladesh



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Bangladesh



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Bangladesh



Sub-types

Specimen test



ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)


## Number of specimens positive for influenza by subtypes and the percentage positive, Bangladesh



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Bhutan



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Bhutan



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
 WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Bhutan



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Bhutan



Sub-types

Specimen test

ILI



SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)


## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, DPR Korea



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, DPR Korea



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, DPR Korea



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, India



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, India



Sub-types

Specimen test

ILI



SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025


WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, India



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, India



Sub-types

Specimen test

ILI




SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025


WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Maldives



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)


## Number of specimens positive for influenza by subtypes and the percentage positive, Maldives



Sub-types




Specimen test



ILI



SARI




SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Myanmar



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Myanmar



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Myanmar



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Myanmar



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of influenza-like illness (ILI) cases , Nepal



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of severe acute respiratory infection (SARI) cases , Nepal




● SARI cases — Proportion of SARI cases per 100 inpatients




Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Nepal



## Number of specimens positive for influenza by subtypes and the percentage positive, Nepal



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Sri Lanka




● ILI cases — Proportion of ILI cases per 1000 outpatients



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
 WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Sri Lanka



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025


WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Sri Lanka



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtype and the percentage positive, Sri Lanka



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Thailand



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Thailand



Sub-types

Specimen test


ILI

SARI


SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Thailand



## Number of specimens positive for influenza by subtypes and the percentage positive, Thailand



Sub-types

Specimen test


ILI

SARI

SARS COV2


Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Timor-Leste



Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 12/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Timor-Leste



Sub-types

Specimen test

ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

If you have any comment or suggestion  
Please write to [SeFlu@who.int](mailto:SeFlu@who.int)